For Venlafaxine Extended Release Capsules
Aurobindo Pharma has announced overly the company has acquired tentative approval from the US Food & Drug Administration to manufacture and market Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg.
Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg are the generic equivalent of Wyeth Pharmaceuticals Inc's Effexor XR Capsules 37.5mg, 75mg and 150mg. Venlafaxine Hydrochloride Extended-release Capsules are showed for the care of drastic depressive disorder (MDD) and falls below the Neurological (CNS) therapeutic category. The product has a market size of something like US$ 2.4 Billion for the twelve cycles endingSeptember 2010 according to IMS.
The tentatively voted for ANDA No. 200834 for Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg was put forward with Paragraph IV certification and is by now short of litigation in the United States District Court for the District of New Jersey [Wyeth LLC v. Aurobindo Pharma Limited, and Aurobindo Pharma USA Inc., Civil Action No. 10-CV-02084]. The product willbe launched subsequent to the litigation settlement.
Aurobindo now has a total of 132 ANDA approvals (99 Final approvals and 33 Tentative approvals) out of USFDA.
The association assembled the current announcement on 24 February 2011.
Read More Here
Aurobindo Pharma has announced overly the company has acquired tentative approval from the US Food & Drug Administration to manufacture and market Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg.
Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg are the generic equivalent of Wyeth Pharmaceuticals Inc's Effexor XR Capsules 37.5mg, 75mg and 150mg. Venlafaxine Hydrochloride Extended-release Capsules are showed for the care of drastic depressive disorder (MDD) and falls below the Neurological (CNS) therapeutic category. The product has a market size of something like US$ 2.4 Billion for the twelve cycles endingSeptember 2010 according to IMS.
The tentatively voted for ANDA No. 200834 for Venlafaxine Hydrochloride Extended-release Capsules 37.5mg, 75mg and 150mg was put forward with Paragraph IV certification and is by now short of litigation in the United States District Court for the District of New Jersey [Wyeth LLC v. Aurobindo Pharma Limited, and Aurobindo Pharma USA Inc., Civil Action No. 10-CV-02084]. The product willbe launched subsequent to the litigation settlement.
Aurobindo now has a total of 132 ANDA approvals (99 Final approvals and 33 Tentative approvals) out of USFDA.
The association assembled the current announcement on 24 February 2011.
Read More Here
1 Comments
I found this article about Aurobindo Pharma’s USFDA approval both informative and insightful. Regulatory approvals from agencies such as the USFDA are significant milestones for pharmaceutical companies, as they reflect compliance with stringent quality standards and open opportunities in global healthcare markets. Aurobindo Pharma has received multiple USFDA approvals over the years for various generic medicines, strengthening its presence in the international pharmaceutical industry. ([Moneycontrol][1])
ReplyDeleteThe post does a great job of highlighting the importance of such developments and their impact on business growth, innovation, and patient access to medicines. Articles like this help readers stay informed about trends in the healthcare and pharmaceutical sectors.
For sports enthusiasts who enjoy following racing events and industry updates, horse racing today is a topic many fans explore to stay connected with the latest racing action and insights.
Thank you for sharing this informative article. I look forward to reading more content on business, healthcare, pharmaceuticals, and industry developments in the future.
[
Thank you for your valuable comment.